Not recruiting yet
Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1
NCT07254650 · University of Texas Southwestern Medical Center · Updated 26 Aug 2026
- What is being tested
- Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block; Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block; Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block
- For
- Lung Cancer (Diagnosis)
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years and older. About 300 people. The full rules are on the registry page.
- Where
- United States
- When
- Starts or started Oct 2026, ends 1 Jan 2028. Registered 28 Nov 2025.
- Results
- None posted yet.
In the researchers' words
The goal of this clinical trial is to assess how the location of local anesthetic medication affects pain control capabilities in adult patients undergoing thoracic(chest)-only minimally invasive surgery. The main questions it aims to answer are: * Is pain decreased when local analgesia is provided as a combination of serratus anterior plane block and intercostal nerve block when compared to either block administered individually? * How does location of local analgesia administration impact length-of-stay, cost-of-care, and quality-of-life? Researchers will compare three treatment options including long-acting local anesthetic (Exparel®) administered as (1) intercostal nerve block, (2) serratus anterior plane block, or (3) combination of intercostal nerve block and serratus anterior plane block to see if pain and opioid use are reduced dependent upon treatment group. All participants will receive a local anesthetic nerve block. Participants will be asked to describe their pain after surgery and to answer various questionnaires before and after surgery.
Sites
- Clements University Hospital at University of Texas Southwestern Medical CenterDallas, Texas, United States
